PAVmed Inc. (PAVM)
0.64
0.04 (6.84%)
At close: Jan 15, 2025, 2:53 PM
undefined% (undefined)
| Bid | 0.64 |
| Market Cap | 7.06M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.14 |
| PE Ratio (ttm) | -0.56 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.64 |
| Volume | 114,649 |
| Avg. Volume (20D) | 147,249 |
| Open | 0.60 |
| Previous Close | 0.60 |
| Day's Range | 0.60 - 0.64 |
| 52-Week Range | 0.57 - 3.50 |
| Beta | undefined |
About PAVM
PAVmed Inc. operates as a medical device company in the United States. The company's lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett's Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation...
Industry Medical - Devices
Sector Healthcare
IPO Date Jul 27, 2016
Employees 107
Stock Exchange NASDAQ
Ticker Symbol PAVM
Website https://www.pavmed.com
Analyst Forecast
According to 1 analyst ratings, the average rating for PAVM stock is "Buy." The 12-month stock price forecast is $19, which is an increase of 2880.39% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
Next Earnings Release
PAVmed Inc. is scheduled to release its earnings on Mar 25, 2025,
after market closes.
Analysts project revenue of $1.46M, reflecting a 39.18% YoY growth and earnings per share of -1.05, making a -21.05% decrease YoY.
Analysts project revenue of $1.46M, reflecting a 39.18% YoY growth and earnings per share of -1.05, making a -21.05% decrease YoY.
8 months ago ·
Source
+15.63%
PAVmed shares are trading higher after the company...
Unlock content with
Pro Subscription
